Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

B. Besse; C. Springfeld; C. Baik; A. Hervieu; B. Solomon; V. Moreno; L. Bazhenova; K. Goto; Y. C. Kim; S. Lu; M. Sun; D. Trone; S. Thamake; B. C. Cho; A. de Langen; S. Popat; J. Wolf; D. Moro-Sibilot; J. Fang; A. Drilon

doi:10.1016/S0959-8049(22)01000-0

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

B. Besse, C. Springfeld, C. Baik, A. Hervieu, B. Solomon, V. Moreno, L. Bazhenova, K. Goto, Y. C. Kim, S. Lu, M. Sun, D. Trone, S. Thamake, B. C. Cho, A. de Langen, S. Popat, J. Wolf, D. Moro-Sibilot, J. Fang, A. Drilon

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	S75-S76
journal	European Journal of Cancer
Volume	174
Les DOIs	https://doi.org/10.1016/S0959-8049(22)01000-0
état	Publié - 1 oct. 2022

Accès au document

10.1016/S0959-8049(22)01000-0

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Besse, B., Springfeld, C., Baik, C., Hervieu, A., Solomon, B., Moreno, V., Bazhenova, L., Goto, K., Kim, Y. C., Lu, S., Sun, M., Trone, D., Thamake, S., Cho, B. C., de Langen, A., Popat, S., Wolf, J., Moro-Sibilot, D., Fang, J., & Drilon, A. (2022). Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). European Journal of Cancer, 174, S75-S76. https://doi.org/10.1016/S0959-8049(22)01000-0

@article{86fe7d36e981401b817883833cd1d90c,

title = "Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-na{\"i}ve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)",

author = "B. Besse and C. Springfeld and C. Baik and A. Hervieu and B. Solomon and V. Moreno and L. Bazhenova and K. Goto and Kim, {Y. C.} and S. Lu and M. Sun and D. Trone and S. Thamake and Cho, {B. C.} and {de Langen}, A. and S. Popat and J. Wolf and D. Moro-Sibilot and J. Fang and A. Drilon",

year = "2022",

month = oct,

day = "1",

doi = "10.1016/S0959-8049(22)01000-0",

language = "English",

volume = "174",

pages = "S75--S76",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Besse, B, Springfeld, C, Baik, C, Hervieu, A, Solomon, B, Moreno, V, Bazhenova, L, Goto, K, Kim, YC, Lu, S, Sun, M, Trone, D, Thamake, S, Cho, BC, de Langen, A, Popat, S, Wolf, J, Moro-Sibilot, D, Fang, J & Drilon, A 2022, 'Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)', European Journal of Cancer, VOL. 174, p. S75-S76. https://doi.org/10.1016/S0959-8049(22)01000-0

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). / Besse, B.; Springfeld, C.; Baik, C. et al.
Dans: European Journal of Cancer, Vol 174, 01.10.2022, p. S75-S76.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - Update from the ongoing phase 1/2 registrational trial of repotrectinib

T2 - results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

AU - Besse, B.

AU - Springfeld, C.

AU - Baik, C.

AU - Hervieu, A.

AU - Solomon, B.

AU - Moreno, V.

AU - Bazhenova, L.

AU - Goto, K.

AU - Kim, Y. C.

AU - Lu, S.

AU - Sun, M.

AU - Trone, D.

AU - Thamake, S.

AU - Cho, B. C.

AU - de Langen, A.

AU - Popat, S.

AU - Wolf, J.

AU - Moro-Sibilot, D.

AU - Fang, J.

AU - Drilon, A.

PY - 2022/10/1

Y1 - 2022/10/1

UR - http://www.scopus.com/inward/record.url?scp=85140461432&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)01000-0

DO - 10.1016/S0959-8049(22)01000-0

M3 - Article

AN - SCOPUS:85140461432

SN - 0959-8049

VL - 174

SP - S75-S76

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -